沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的临床研究

发布时间：2018-05-15 07:16

  本文选题：沙美特罗替卡松 + 慢性阻塞性肺疾病　； 参考：《中国临床药理学杂志》2017年11期

【摘要】：目的观察沙美特罗替卡松治疗慢性阻塞性肺疾病(COPD)临床疗效及安全性。方法将70例COPD患者随机分为对照组35例与试验组35例。2组均予以常规治疗以及对症治疗;对照组予以噻托溴铵粉雾剂,每次一吸(18μg),qd;试验组予以沙美特罗替卡松粉吸入剂,每次一吸(50μg),qd。2组患者一个周期均为28 d,共治疗3个周期。比较2组患者的临床疗效、治疗前后用力肺活量(FVC)、一秒用力呼气容积(FEV1)、最大呼气峰流速值(PEF)、FEV1/FVC、FEV1及PEF占预计值百分比、圣·乔治医院呼吸问题调查问卷(SGRQ)、多因素分级系统(BODE)指数评分,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为91.43%(32/35例)和77.14%(27/35例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的FEV1分别为(1.86±0.19),(1.42±0.17)L;FEV1/FVC分别为(42.93±4.25)%,(39.73±3.68)%;PEF分别为(3.69±0.37),(3.11±0.35)L;FEV1/预计值分别为(48.57±4.97)%,(44.47±4.51)%;PEF/预计值分别为(48.92±5.05)%,(41.53±4.55)%;SGBQ分别为(44.97±4.96),(42.01±4.67)分;BODE分别为(5.98±0.59),(5.67±0.59)分,差异均有统计学意义(均P0.05)。试验组出现头痛1例,震颤1例,心悸1例,总药物不良反应发生率为8.57%(3/35例),对照组出现头痛2例,心悸1例,声音嘶哑2例,总药物不良反应发生率为14.29%(5/35例),2组患者的药物不良反应发生率比较,差异无统计学意义(P0.05)。结论沙美特罗替卡松治疗COPD的临床疗效显著,安全性高。
[Abstract]:Objective to observe the efficacy and safety of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Methods 70 patients with COPD were randomly divided into control group (n = 35) and experimental group (n = 35). One cycle was 28 days in 50 渭 g / g QD.2 group, and there were 3 cycles of treatment. The clinical efficacy of the two groups was compared. Forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1 / FEV1, FEV1 / FVC1 / FEV1 and PEF were compared between the two groups before and after treatment. The respiratory questionnaire of St. George's Hospital included SGRQN, multivariate grading system and BODEI score, and the incidence of adverse drug reactions (ADRs). Results after treatment, the total effective rates of the test group and the control group were 91.43 / 32 / 35 and 77.14 / 35, respectively. The difference was statistically significant (P 0.05). 娌荤枟鍚，

本文编号：1891511